Home
About
Overview
Sharing Data
ORCID
Help
History (3)
Demyelinating disease and psoriasis: interferon versus dimethyl fumarate.
Metabotropic glutamate receptor (mGluR)-mediated potentiation of cyclic AMP responses does not require phosphoinositide hydrolysis: mediation by a group II-like mGluR.
Synergy between Hematopoietic and Radioresistant Stromal Cells Is Required for Autoimmune Manifestations of DNase II-/-IFNaR-/- Mice.
See All 3 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Demyelinating disease and psoriasis: interferon versus dimethyl fumarate.
Howard LG, Bomprezzi R. Demyelinating disease and psoriasis: interferon versus dimethyl fumarate. J Neurol Sci. 2014 Aug 15; 343(1-2):230-1.
View in:
PubMed
subject areas
Adult
Antiviral Agents
Demyelinating Diseases
Dimethyl Fumarate
Fumarates
Humans
Immunosuppressive Agents
Interferons
Magnetic Resonance Imaging
Male
Psoriasis
authors with profiles
Roberto Bomprezzi MD, PhD